Literature DB >> 1378437

Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease.

D Chattopadhyay1, D B Evans, M R Deibel, A F Vosters, F M Eckenrode, H M Einspahr, J O Hui, A G Tomasselli, H A Zurcher-Neely, R L Heinrikson.   

Abstract

Active recombinant reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) with an amino-terminal extension containing a hexa-histidine sequence has been prepared in milligram quantities in a pure heterodimeric (p66/p51) form by coordinated applications of immobilized metal affinity chromatography (IMAC) and HIV-1 protease treatment. The precursor protein, isolated from extracts of recombinant Escherichia coli by IMAC in a predominantly unprocessed form (p66), migrated on sodium dodecyl sulfate-polyacrylamide gels as a 66-kDa band with minor heterogeneity at lower relative molecular mass. Incubation of this protein with recombinant HIV-1 protease produced a stable heterodimeric RT that was purified in a single step by IMAC. The purified protein retained both RT and RNase H activity, and kinetic parameters (Km and Vmax) were measured with both RNA-dependent DNA polymerization and RNase H activity assays. Carboxyl-terminal sequencing of purified heterodimeric RT indicated that one subunit is intact p66, whereas the other, p51, is a truncated form of p66 that terminates at residue Phe440. Analysis of the HIV-1 protease digest revealed two cleavage sites, at Tyr483-Leu484 and Tyr532-Leu533, in addition to the site at Phe440-Tyr441 that is cleaved to produce p51.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378437

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843.

Authors:  I W Althaus; R J LeMay; A J Gonzales; M R Deibel; S K Sharma; F J Kezdy; L Resnick; M E Busso; P A Aristoff; F Reusser
Journal:  Experientia       Date:  1992-12-01

2.  HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

Authors:  Isabel Olivares; Alok Mulky; Peter I Boross; József Tözsér; John C Kappes; Cecilio López-Galíndez; Luis Menéndez-Arias
Journal:  J Mol Biol       Date:  2007-07-03       Impact factor: 5.469

3.  Characterization of HIV-1 reverse transcriptase with antibodies indicates conformational differences between the RNAse H domains of p 66 and p 15.

Authors:  A M Szilvay; S Nornes; A Kannapiran; B I Haukanes; C Endresen; D E Helland
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  The p66 immature precursor of HIV-1 reverse transcriptase.

Authors:  Naima G Sharaf; Eric Poliner; Ryan L Slack; Martin T Christen; In-Ja L Byeon; Michael A Parniak; Angela M Gronenborn; Rieko Ishima
Journal:  Proteins       Date:  2014-05-12

5.  Effect of tRNA on the Maturation of HIV-1 Reverse Transcriptase.

Authors:  Tatiana V Ilina; Ryan L Slack; John H Elder; Stefan G Sarafianos; Michael A Parniak; Rieko Ishima
Journal:  J Mol Biol       Date:  2018-05-08       Impact factor: 5.469

6.  A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.

Authors:  T J Dueweke; T Pushkarskaya; S M Poppe; S M Swaney; J Q Zhao; I S Chen; M Stevenson; W G Tarpley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

7.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

Authors:  T J Dueweke; S M Poppe; D L Romero; S M Swaney; A G So; K M Downey; I W Althaus; F Reusser; M Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

8.  Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.

Authors:  Sidhartha Chaudhury; Jeffrey J Gray
Journal:  Structure       Date:  2009-12-09       Impact factor: 5.006

9.  The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site.

Authors:  Naima G Sharaf; Zhaoyong Xi; Rieko Ishima; Angela M Gronenborn
Journal:  Proteins       Date:  2017-09-26

10.  (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.

Authors:  R A Olmsted; D E Slade; L A Kopta; S M Poppe; T J Poel; S W Newport; K B Rank; C Biles; R A Morge; T J Dueweke; Y Yagi; D L Romero; R C Thomas; S K Sharma; W G Tarpley
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.